LAS189962

Almirall, S.A. · Phase 2 active Small molecule

At a glance

Generic name	LAS189962
Sponsor	Almirall, S.A.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis (PHASE2)
Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections (PHASE2)
Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LAS189962 CI brief — competitive landscape report
LAS189962 updates RSS · CI watch RSS
Almirall, S.A. portfolio CI